T, NK, and B-cell reconstitution and cytokine evolution 24 to 36 months after R-CHOP therapy
| . | At diagnosis . | 24-36 months∗ . | P value . |
|---|---|---|---|
| n | 27 | 27 | |
| Immunoglobulin levels | |||
| IgG (g/L) | 14.9 (10.8- 17.2) | 11.8 (9.6-14.2) | <.001 |
| IgA (g/L) | 2.5 (2.0-3.2) | 2.1 (1.5-2.6) | .002 |
| IgM (g/L) | 0.9 (0.5-1.7) | 0.7 (0.4-1.0) | .012 |
| Leucocytes CD45+ (× 109/L) | 1.40 (0.85- 1.70) | 1.88 (1.27- 2.33) | .014 |
| T lymphocytes | |||
| CD3+ T lymphocytes (× 109/L) | 1.07 (0.64-1.46) | 1.30 (0.96-1.71) | .11 |
| CD3+CD4+ T lymphocytes (× 109/L) | 0.29 (0.2-0.48) | 0.4 (0.25-0.54) | .44 |
| CD3+CD8+ T lymphocytes (× 109/L) | 0.62 (0.42-1.01) | 0.87 (0.58-1.21) | .13 |
| B lymphocytes | |||
| CD19+ B lymphocytes (× 109/L) | 0.10 (0.04-0.23) | 0.33 (0.22-0.41) | .001 |
| CD19+IgD+CD27− among B lymphocytes (%) | 77.5 (65.0- 87.0) | 85.2 (77.5- 90.4) | .009 |
| CD19+IgD+CD27+ among B lymphocytes (%) | 5.0 (2.0-10.2) | 3.0 (1.9-4.9) | .036 |
| CD19+IgD−CD27+ among B lymphocytes (%) | 10.5 (4.8-16.5) | 6.5 (4.2-9.7) | .031 |
| NK lymphocytes | |||
| NK lymphocytes (× 109/L) | 0.09 (0.06- 0.14) | 0.15 (0.12-0.2) | .001 |
| Cytokines | |||
| IL-6 blood level (pg/mL) | 9.8 (6.0-21.7) | 4.1 (1.4-8.7) | .14 |
| IL-10 blood level (pg/mL) | 24.8 (9.4-35.0) | 7.2 (5.3-12.7) | <.001 |
| BAFF blood level (pg/mL) | 847.0 (656.2- 1241.0) | 604.8 (494.2- 920.0) | .200 |
| . | At diagnosis . | 24-36 months∗ . | P value . |
|---|---|---|---|
| n | 27 | 27 | |
| Immunoglobulin levels | |||
| IgG (g/L) | 14.9 (10.8- 17.2) | 11.8 (9.6-14.2) | <.001 |
| IgA (g/L) | 2.5 (2.0-3.2) | 2.1 (1.5-2.6) | .002 |
| IgM (g/L) | 0.9 (0.5-1.7) | 0.7 (0.4-1.0) | .012 |
| Leucocytes CD45+ (× 109/L) | 1.40 (0.85- 1.70) | 1.88 (1.27- 2.33) | .014 |
| T lymphocytes | |||
| CD3+ T lymphocytes (× 109/L) | 1.07 (0.64-1.46) | 1.30 (0.96-1.71) | .11 |
| CD3+CD4+ T lymphocytes (× 109/L) | 0.29 (0.2-0.48) | 0.4 (0.25-0.54) | .44 |
| CD3+CD8+ T lymphocytes (× 109/L) | 0.62 (0.42-1.01) | 0.87 (0.58-1.21) | .13 |
| B lymphocytes | |||
| CD19+ B lymphocytes (× 109/L) | 0.10 (0.04-0.23) | 0.33 (0.22-0.41) | .001 |
| CD19+IgD+CD27− among B lymphocytes (%) | 77.5 (65.0- 87.0) | 85.2 (77.5- 90.4) | .009 |
| CD19+IgD+CD27+ among B lymphocytes (%) | 5.0 (2.0-10.2) | 3.0 (1.9-4.9) | .036 |
| CD19+IgD−CD27+ among B lymphocytes (%) | 10.5 (4.8-16.5) | 6.5 (4.2-9.7) | .031 |
| NK lymphocytes | |||
| NK lymphocytes (× 109/L) | 0.09 (0.06- 0.14) | 0.15 (0.12-0.2) | .001 |
| Cytokines | |||
| IL-6 blood level (pg/mL) | 9.8 (6.0-21.7) | 4.1 (1.4-8.7) | .14 |
| IL-10 blood level (pg/mL) | 24.8 (9.4-35.0) | 7.2 (5.3-12.7) | <.001 |
| BAFF blood level (pg/mL) | 847.0 (656.2- 1241.0) | 604.8 (494.2- 920.0) | .200 |
The results are presented as median [IQR]. Statistical analyses were conducted using paired Wilcoxon tests.
When multiple values were available for a patient, the mean value was used.